{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:32:02Z","timestamp":1783031522381,"version":"3.54.6"},"publisher-location":"Berlin, Heidelberg","reference-count":37,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642380068","type":"print"},{"value":"9783642380075","type":"electronic"}],"license":[{"start":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T00:00:00Z","timestamp":1381449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T00:00:00Z","timestamp":1381449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-3-642-38007-5_25","type":"book-chapter","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T17:20:06Z","timestamp":1381512006000},"page":"443-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Novel Approaches in Melanoma Prevention and Therapy"],"prefix":"10.1007","author":[{"given":"Antonio M.","family":"Grimaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela B.","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sancy","family":"Leachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,11]]},"reference":[{"issue":"6","key":"25_CR1","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1055-9965.EPI-09-1249","volume":"19","author":"DA Lazovich","year":"2010","unstructured":"Lazovich DA, Vogel RI, Berwick M, Weinstock MA, Anderson KE, Warshaw EM (2010). Indoor tanning and Risk of Melanoma: A case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev 19(6):1557\u20131568.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"25_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/01.cco.0000208791.22442.09","volume":"18","author":"L Pho","year":"2006","unstructured":"Pho L, Grossman D, Leachman SA (2006) Melanoma genetics: a review of genetic factors and clinical phenotypesin familian melanomas. Curr Opin Oncol  18(2):173\u2013179","journal-title":"Curr Opin Oncol"},{"key":"25_CR3","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635\u20133648","journal-title":"J Clin Oncol"},{"key":"25_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1034\/j.1600-0749.2003.08363.x","volume":"16","author":"FR Gruijl","year":"2003","unstructured":"Gruijl FR (2003) IL-40 UV carcinogenesis and melanocytes. Pigment Cell Res 16:591","journal-title":"Pigment Cell Res"},{"issue":"8","key":"25_CR5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1470-2045(09)70213-X","volume":"10","author":"F Ghissassi","year":"2009","unstructured":"Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V (2009) On behalf of the WHO international agency for research on cancer monograph working group. Special report: policy a review of human carcinogens\u2014Part D: radiation. Lancet Oncol, 10(8):751\u2013752","journal-title":"Lancet Oncol"},{"key":"25_CR6","unstructured":"WHO (2006) International agency for fresearch on cancer. exposure to artificial UV radiation and skin cancer. IARC working group reports. Vol 1"},{"key":"25_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0891-5849(01)00650-5","volume":"31","author":"FL Meyskens Jr","year":"2001","unstructured":"Meyskens FL, Jr McNulty SE, Buckmeier JA, Tohidian NB, Spillane TJ, Kahlon RS, Gonzalez RI (2001) Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med 31:799\u2013808","journal-title":"Free Radic Biol Med"},{"key":"25_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2133.2010.10057.x","volume":"164","author":"M Rizwan","year":"2011","unstructured":"Rizwan M, Rodriguez-Blanco I, Harbottle A, Birch-Machin MA, Watson RE, Rhodes LE (2011) Tomato paste rich in lycopene protects against cutaneous photo damage in humans in vivo: a randomized controlled trial. Br J Dermatol 164:154\u2013162","journal-title":"Br J Dermatol"},{"key":"25_CR9","doi-asserted-by":"publisher","first-page":"17500","DOI":"10.1073\/pnas.0708710104","volume":"104","author":"P Talalay","year":"2007","unstructured":"Talalay P, Fahey JW, Healy ZR, Wehage SL, Benedict AL, Min C, Dinkova-Kostova AT (2007) Sulforaphane mobilizes cellular defenses that protect skin against damage by UV radiation. Proc Natl Acad Sci USA 104: 17500\u201317505","journal-title":"Proc Natl Acad Sci U S A"},{"key":"25_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1039\/b9pp00130a","volume":"9","author":"AT Dinkova-Kostova","year":"2010","unstructured":"Dinkova-Kostova AT, JW Fahey, AL Benedict, SN Jenkins, L Ye, SL Wehage,  P Talalay (2010) Dietary glucoraphanin-rich broccoli sprout extracts protect against UV radiation-induced skin carcinogenesis in SKH-1 hairless mice. Photochemical and Photobiological Sciences 9: 597\u2013600","journal-title":"Photochem Photobiol Sci"},{"key":"25_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00403-009-1001-3","volume":"302","author":"JA Nichols","year":"2010","unstructured":"Nichols JA, Katyar SK (2010) Skin photoprotection and natural polyphenol:anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res 302(2):71\u201383","journal-title":"Arch Dermatol Res"},{"key":"25_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0304-3835(92)90212-E","volume":"65","author":"S Taniguchi","year":"1992","unstructured":"Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H, Shimokawa R (1992) Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65:51\u201354","journal-title":"Cancer Lett"},{"key":"25_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nrm1498","volume":"5","author":"C Wellbrock","year":"2004","unstructured":"Wellbrock C, Karasarides M, Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875\u2013885","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"25_CR14","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1210\/jc.2003-030305","volume":"88","author":"H Namba","year":"2003","unstructured":"Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88(9):4393\u20134397. doi:10.1210\/jc.2003-030305.PMID12970315","journal-title":"J Clin Endocrinol Metab"},{"key":"25_CR15","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Br\u00f6cker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med, 353:2135\u20132147","journal-title":"N Engl J Med"},{"key":"25_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/jmg.2003.016667","volume":"41","author":"RH Edwards","year":"2004","unstructured":"Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, Nussen-Lee S, Haupt HM, Martin AM, Herlyn M, Lessin SR, Weber BL (2004) Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 41:270\u2013272","journal-title":"J Med Genet"},{"key":"25_CR17","first-page":"72876","volume":"44","author":"Y Cohen","year":"2003","unstructured":"Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe\u2019er J, Sidransky D (2003) Lack of BRAF mutation in primary uveal melanoma invest. Ophthalmol Vis Sci, 44:72876\u20132878","journal-title":"Ophthalmol Vis Sci"},{"key":"25_CR18","unstructured":"Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL (2003) Absence of BRAF and NRAS mutations in uveal melanoma. cancer res, 63(18):5761\u20135766"},{"issue":"24","key":"25_CR19","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1093\/jnci\/djg123","volume":"95","author":"JL Maldonado","year":"2003","unstructured":"Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC (2003) Determinants of BRAF Mutations in Primary Melanomas. J Natl Cancer Inst 95(24):1878\u20131890","journal-title":"J Natl Cancer Inst"},{"key":"25_CR20","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1038\/onc.2011.160","volume":"30","author":"G Maurer","year":"2011","unstructured":"Maurer G, Tarkowski B, Baccarini M (2011) Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 30:3477\u20133488","journal-title":"Oncogene"},{"issue":"10","key":"25_CR21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"1","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. JCO April 1, 29(10):1239\u20131246","journal-title":"JCO April"},{"issue":"1","key":"25_CR22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00008390-200102000-00009","volume":"11","author":"M Huncharek","year":"2001","unstructured":"Huncharek M, Caubet JF, McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3,273 patients from 20 randomized trials. Melanoma Res, 11(1):75\u201381","journal-title":"Melanoma Res"},{"key":"25_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/OTT.S4833","volume":"3","author":"AA Tarhini","year":"2010","unstructured":"Tarhini AA, Iqbal F (2010) CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 3:15\u201325","journal-title":"Onco Targets Ther"},{"key":"25_CR24","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2009-0028","volume":"8","author":"C Robert","year":"2009","unstructured":"Robert C, Ghiringhelli F (2009) What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 8:848\u2013861","journal-title":"Oncologist"},{"key":"25_CR25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596\u2013599","journal-title":"Nature"},{"key":"25_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O\u2019Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809\u2013819","journal-title":"N Engl J Med"},{"key":"25_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with Vemurafenib. N Engl J Med 366:707\u2013714","journal-title":"N Engl J Med"},{"key":"25_CR28","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516","journal-title":"N Engl J Med"},{"key":"25_CR29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2010.28.15_suppl.8503","volume":"28","author":"R Kefford","year":"2010","unstructured":"Kefford R et al (2010) Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28:15\u00a0s, (suppl; abstr 8503)","journal-title":"J Clin Oncol"},{"key":"25_CR30","unstructured":"Amiri P, Aikawa ME, Dove J et al (2006) CHIR-265 is a potent selective inhibitor of c-Raf\/B-Raf\/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with RAS\/RAF pathway mutations. Proc Am Assoc Cancer Res, 47 (Abstract 4855)"},{"key":"25_CR31","doi-asserted-by":"crossref","unstructured":"Stuart DD, Li N, Poon DJ, Aardalen K, Kaufman S, Merritt H, Salangsang F, Lorenzana E, Li A, Ghoddusi M, Caponigro G, Sun F, Kulkarni S, Kakar S, Turner N, Zang R, Tellew J, Pryer N. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor.#3790","DOI":"10.1158\/1538-7445.AM2012-3790"},{"key":"25_CR32","unstructured":"http:\/\/www.cancertrialsaustralia.com\/Clinical-Trials-Register.aspx. Cancer Trials Australia"},{"key":"25_CR33","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01400451?term=Vemurafinib&rank=5.U.S. NIH"},{"key":"25_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","volume":"23","author":"R Halaban","year":"2010","unstructured":"Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M (2010) PLX4032, a selective BRAF (V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23:190\u2013200","journal-title":"Pigment Cell Melanoma Res"},{"key":"25_CR35","doi-asserted-by":"crossref","unstructured":"Infante JR et al (2011) Phase I\/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1\/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 29: (suppl; abstr CRA8503)","DOI":"10.1200\/jco.2011.29.15_suppl.cra8503"},{"key":"25_CR36","doi-asserted-by":"crossref","unstructured":"Niehr et al (2011) Combination therapy with Vemurafinib (PLX4032\/RG7204) and Metformin in melanoma cell lines with distinct driver mutations. J Trans Med, 9:76","DOI":"10.1186\/1479-5876-9-76"},{"key":"25_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1479-5876-8-38","volume":"8","author":"PA Ascierto","year":"2010","unstructured":"Ascierto PA, Streicher HZ, Sznol M (2010) Melanoma: a model for testing new agents in combination therapies. J Trans Med 8:38","journal-title":"J Trans Med"}],"container-title":["Cancer Treatment and Research","Advances in Nutrition and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-38007-5_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T17:18:46Z","timestamp":1706203126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-38007-5_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,11]]},"ISBN":["9783642380068","9783642380075"],"references-count":37,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-38007-5_25","relation":{},"ISSN":["0927-3042"],"issn-type":[{"value":"0927-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,11]]},"assertion":[{"value":"11 October 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}